This variability likely reflects differences in study populations, such as the presence or absence of T2DM, degree of obesity, sex distribution, and comorbid conditions, as well as differences in intervention characteristics, including the type, dose, and duration of GLP-1 RA therapy
Payer-specific guidelines for HCPCS Code J3490 No two payers process J3490 identically
Retatrutide may cause acid reflux symptoms in some individuals because it slows gastric emptying via GLP-1 receptor activation, keeping stomach contents including acid in the stomach for longer
Single-cell RNA-sequencing of circulating tumour cells: a practical guide to workflow and translational applications
Findings from research models do not establish safety or efficacy in humans